 |
|
|
| |
Scaling a non-human primate physiologically-based pharmacokinetic model of extended-release MK-2048 and combination MK-2048/vicriviroc (MK-2048A) intravaginal rings into humans using phase 1 MTN-027 and MTN-028 studies
|
| |
| |
Presented at the 5th Conference on HIV Research for Prevention (HIVR4P); October 6-10, 2024; Lima, Peru
K. Adams1 , S. Patel2,3 , L. Rohan2,3.4 , R. Bies1
1.) School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, US 2.) Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, US
3.) Magee-Womens Research Institute, US 4.) Department of Obstetrics, Gynecology, & Reproductive Sciences, School of Medicine, University of Pittsburgh, US
|
| |
|
|
|
|
|
